Author: matias iglicki (Argentina)
Co-authors: prof Paolo Lanzetta, Catharina Busch, Marco Lupidi, Jay Chahhblani, Dinah Zur, Prof Anat Loewestein
We aimed to compare visual and anatomical outcome in vitrectomized and non- vitrectomized eyes treated with Dexamethasone (DEX) implant due to diabetic macular edema (DME). Design: Multicenter, retrospective, interventional study. Participants: 236 eyes from 234 patients with DME with or without previous vitrectomy performed with a follow up of 12 months.
Multicenter, retrospective, interventional study. Participants: 236 eyes from 234 patients with DME with or without previous vitrectomy performed with a follow up of at least 12 months involving multiple sites
Methods: Main outcome measures: Change from baseline best corrected visual acuity (BCVA) and central subfoveal thickness (CST) over follow-up period. Secondary outcomes: cataract rate formation, intraocular pressure increase, number of implants needed.
The non-vitrectomized group included 130 eyes (55.1%), the vitrectomized group included 106 eyes (44.9%). The groups were well balanced for age and gender (p=0.540, and p=0.053, respectively). Both groups showed statistically significant improvement in BCVA and CST (for all groups: p<0.001). There was no significant difference between the groups in terms of change in vision (p=0.89) and anatomy (p=0.65). The mean number of DEX implants given during follow-up was 3.5 in both groups, and there was no significant difference between the groups (p=0.81).
In patients with DME, we demonstrated similar anatomical and functional efficacy of DEX implant in non-vitrectomized and vitrectomized eyes. Its efficacy was not decreased by the consequences of full vitrectomy for Diabetic retinopathy complications. Safety profile was very well balanced between the groups.
Allergan – Consultant -Bayer - Consultant -Novartis- Consultant -Regeneron- PI -Genentech-PI -TSK Laboratory Europe B.V. consultan